Physician profile
Michael Toboni
NPI 1750769568
$8,454.97
in general payments reported to CMS, 2019-2025
8 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.46 · 2021: $138 · 2023: $873 · 2024: $6,948 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,750 · Travel and Lodging: $1,761 · Grant: $858 · Food and Beverage: $452 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,750.00 |
| Travel and Lodging | $1,761.30 |
| Grant | $857.50 |
| Food and Beverage | $452.36 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,821.35 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $877.92 | 2023-2024 | Lynparza |
| Caris Mpi, INC. | $400.00 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $123.35 | 2021 | |
| Karyopharm Therapeutics INC. | $121.31 | 2024 | Xpovio |
| Merck Sharp & Dohme LLC | $95.46 | 2019 | |
| Immunogen, INC. | $15.58 | 2023 | Elahere |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Toboni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.